Impact of body composition on COVID-19 susceptibility and severity: a two-sample multivariable Mendelian randomization study

Dennis Freuer^{1,2*}, Jakob Linseisen^{1,2}, Christa Meisinger^{1,2}

- 1: Chair of Epidemiology at UNIKA-T Augsburg, Ludwig-Maximilians-Universität München, 86156 Augsburg, 80539 München, Germany
- 2: Independent Research Group Clinical Epidemiology, Helmholtz Center Munich, German Research Centre for Environmental Health, 85764 Neuherberg, Germany

ABSTRACT

Objectives

Recent studies suggested obesity to be a possible risk factor for COVID-19 disease in the wake of the coronavirus (SARS-CoV-2) infection. However, the causality and especially the role of body fat distribution in this context is still unclear. Thus, using a univariable as well as multivariable two-sample Mendelian randomization (MR) approach, we investigated for the first time the causal impact of body composition on the susceptibility and severity of COVID-19.

Methods

As indicators of overall and abdominal obesity we considered the measures body mass index (BMI), waist circumference (WC), and trunk fat ratio (TFR). Summary statistics of genome-wide association studies (GWASs) for these body composition measures were drawn from the GIANT consortium and UK Biobank, while for susceptibility and severity due to COVID-19 disease data from the COVID-19 Host Genetics Initiative was used. Total and direct causal effect estimates were calculated using Single Nucleotide Polymorphisms (SNPs), sensitivity analyses were done applying several robust MR techniques and mediation effects of type 2 diabetes (T2D) and cardiovascular diseases (CVD) were investigated within multivariable MR analyses.

Results

Genetically predicted BMI was strongly associated with both, susceptibility (OR=1.31 per 1 SD increase; 95% CI: 1.15-1.50; P-value= $7.3 \cdot 10^{-5}$) and hospitalization (OR=1.62 per 1 SD increase; 95% CI: 1.33-1.99; P-value= $2.8 \cdot 10^{-6}$) even after adjustment for genetically predicted visceral obesity traits. These associations were neither mediated substantially by T2D nor by CVD. Finally, total but not direct effects of visceral body fat on outcomes could be detected.

Conclusions

This study provides strong evidence for a causal impact of overall obesity on the susceptibility and severity of COVID-19 disease. The impact of abdominal obesity was weaker and disappeared after adjustment for BMI. Therefore, obese people should be regarded as a high-risk group. Future research is necessary to investigate the underlying mechanisms linking obesity with COVID-19.

2

INTRODUCTION

The global COVID-19 pandemic due to an outbreak of a coronavirus infection (SARS-CoV-2) causes serious conditions such as respiratory failure, pneumonia, and is associated with a high number of deaths¹. Therefore, it is essential to identify risk factors associated with a higher susceptibility to COVID-19 or a more severe course of the disease and subsequently to identify high risk groups that require special protection². Prior observational studies and meta-analyses found that SARS-CoV-2-patients with chronic diseases such as diabetes, cardiovascular diseases, chronic kidney disease, and respiratory diseases might be at increased risk of disease severity and mortality^{3,4}. Recent observational studies and systematic reviews and meta-analyses reported that also obese people may be vulnerable to a more severe COVID-19 disease course^{5,8}. However, results were inconsistent on the association between BMI and COVID-19⁹⁻¹². Using a Mendelian randomization approach, for very severe cases of COVID-19 patients with respiratory failure, BMI was already shown to have a causal impact^{13,14}. Another MR-study suggested genetically predicted BMI as causal risk factor for susceptibility and severity of COVID-19¹⁵. However, so far, research on the causal impact of body fat distribution on the susceptibility and severity of a COVID-19 disease is missing.

A Mendelian randomization approach offers the possibility to examine causality by using genetic variants as instruments, which are explicitly associated with the exposure. Thus, it is possible to minimize confounding and preclude reverse causation because variants are randomly allocated from parents to offspring at conception. In this study we investigated for the first time total as well as direct causal effects of an increase in BMI, waist circumference (WC), and trunk fat ratio (TFR) on the risk of infection and severe course of COVID-19 disease. We disentangled the suggested effects of overall and visceral body fat using refined statistical methods.

METHODS

Study design

In a two-sample Mendelian randomization (MR) approach genetic variants were used to assess total and direct causal effects of obesity considering also body fat distribution as risk factor on COVID-19 susceptibility and hospitalization due to an infection with the SARS- CoV-2 virus. The direct effect is defined as the effect of an exposure on the outcome only via one path (direct) but not via any other path [Figure 1]. By contrast, the total effect

is defined as the sum of all possible paths from the exposure on the outcome. Further details on the MR- and MVMR-design were described elsewhere¹⁶⁻¹⁹.

Obesity measurements and data availability

To quantify obesity and to assess body fat distribution we used three different body composition measures, namely BMI as indicator for overall obesity, and WC and TFR as measures for visceral adiposity. TFR, defined as proportion of body fat in the trunk was calculated by dividing the fat mass of the trunk by total body fat mass that were determined by segmental bioelectrical impedance analysis²⁰. For BMI, the summary statistics of a genome-wide association study (GWAS) conducted by Pulit et al.²¹ including 694,649 participants from the GIANT consortium and UK Biobank [Table 1] were considered. To account for abdominal obesity we considered both the WC-GWAS of Shungin et al.²² based on 232,101 observations from the GIANT consortium and the TFR-GWAS of Rask-Andersen et al.²⁰ with 362,499 subjects from the UK Biobank. The use of both datasets allowed us to replicate and verify the results and thus strengthen evidence. Furthermore, for mediation analyses the latest GWAS for type 2 diabetes (T2D) of the MRC IEU OpenGWAS Project²³ with 12,375 cases and 82,665 controls of the FinnGen Biobank and for cardiovascular disease the summary level data of Schunkert et al.²⁴ with 22,233 cases and 64,762 controls from the CARDIoGRAM consortium were used. Both mediation GWASs has the advantage that there is no sample overlap with the selected datasets of metabolic traits what is important to avoid issues regarding SNP-covariance estimation within mediation analysis²⁵. All datasets include observations in men and women of European ancestry. In all original studies, ethical approval had been obtained.

Selection of genetic instrumental variables for body composition measures

As independent instruments we considered SNPs that were associated with the appropriate exposure at the genome-wide significance threshold $P < 5 \cdot 10^{-8}$ and were not in linkage disequilibrium (LD) using a clumping procedure with the cut-off $r^2 = 0.001$. Therefore, 524 BMI-related, 42 WC-related and 33 TFR-related independent SNPs were considered for univariable MR analyses after removing SNPs with an imputation score ≤ 0.8 and palindromic SNPs with intermediate allele frequencies [Supplementary Tables S1-S3]. These SNPs explained overall 5.51 %, 1.09 %, and 1.25 % of the variance in BMI, WC, and TFR, respectively [Table 1]. Mean F-statistics, as measure

for instrument strength, ranged from 41.69 (TFR) to 72.29 (BMI) indicating strong instruments and therefore low predisposition for weak instruments bias. Even the lowest F-statistic F=28.44 in BMI was above the suggested threshold for sufficient instrument strength of F=10.

GWAS summary statistics for COVID-19 disease

Genetic associations with COVID-19 susceptibility and hospitalization were acquired from the growing COVID-19 Host Genetics Initiative²⁶, which provides publicly accessible summary statistics of GWAS in relation to several COVID-19 outcomes from different studies (e.g. UK Biobank, FinnGen). In the third release from June 29, 2020 in total 6696 positively tested COVID-19 cases (vs. 1073072 controls) and 3199 hospitalized COVID-19 patients due to severe symptoms (vs. 897488 controls) were available. Further information and new releases can be taken from the COVID-19 Host Genetics Initiative²⁶ homepage.

Statistical power

The a priori statistical power for the binary traits susceptibility and hospitalization due to COVID-19 disease was calculated according to Burgess et al.²⁷. Given a type I error of 5 %, the power for susceptibility was higher than for hospitalization and higher for BMI than for WC or TFR regarding the explained variance in exposures as well as the number of cases/controls in the outcomes [Supplementary Table S4]. Therefore, our analyses were sufficiently powered (i.e. > 80 %) when the true OR per one standard deviation of the respective exposure was \geq 1.4 for COVID-19 susceptibility and \geq 1.5 for hospitalization due to COVID-19 in genetically instrumented BMI, WC and TFR.

Statistical analyses

Causal estimates of the relationships between body composition measures and Covid-19 susceptibility as well as severity were calculated, applying an inverse-variance weighted (IVW) meta-analysis using modified second order weights within the radial regression framework. This approach provides the highest statistical power if the key assumptions of the Mendelian randomization are met. To assess and validate these assumptions we performed a series of sensitivity analyses that consider different patterns of violations. Among others, the MR-PRESSO (Pleiotropy RESidual Sum and Outlier) method was used for two issues: the global test (based on observed residual sum of

squares) detected horizontal pleiotropy and the outlier test identified potential outlier SNPs at a threshold of 0.05 [Supplementary Table S5].

Under the Instrument Strength Independent of Direct Effect (InSIDE) assumption, the radial MR-Egger intercept test was applied for assessing directional pleiotropy [Supplementary Table S5]. Substantial heterogeneity within the IVW and MR-Egger methods was quantified and tested using Cochran's as well as Rücker's Q statistics [Supplementary Table S6]. Furthermore, we investigated influential SNPs based on the respective Q statistic and several plots (e.g. radial, funnel, leave-one-out, and SNP-exposure-outcome association plots). If necessary, outliers were excluded as a part of a sensitivity analysis within an iterative approach.

To assess consistency of causal estimates in case of horizontal pleiotropy as well as outlier occurrence, we additionally performed four types of robust estimation methods. The first was the MR-Egger regression, which provides under the InSIDE assumption a consistent estimator, even if there is directional pleiotropy. The second was the weighted median approach that requires at least 50 % of the genetic variants to be valid instruments. The third was the weighted mode method, which is consistent even if less than 50 % of the genetic variants are valid. Fourth, we conducted a many weak instruments analysis using the RAPS (Robust Adjusted Profile Score) method and controlled for systematic pleiotropy in form of overdispersion, if necessary.

Obviously, the used body composition measures for overall and visceral obesity are not independent from each other. Furthermore, the causal effect estimates of these traits on the susceptibility and severity of COVID-19 disease may be mediated through obesity-related diseases. Therefore, to calculate the direct effects of each body composition measure and to investigate possible mediation mechanisms of type 2 diabetes and cardiovascular diseases (CVD), we additionally performed multivariable MR (MVMR) analyses. In the main analysis we performed the robust IVW method with multiplicative random effects, where we mutually adjusted BMI as measure for overall body fat for the association of variants with genetically predicted levels of one of the visceral obesity traits (WC, TFR) or comorbidity (type 2 diabetes, CVD). Within sensitivity analyses the MR-Egger with multiplicative random effects and the Median approach were performed. In addition to this, we determined Q-minimized point estimates that take into account weak instruments and substantial heterogeneity using estimated phenotypic correlations. To assess substantial heterogeneity and directional pleiotropy, we calculated the global Q-statistics and applied the MR-Egger intercept test to all models, respectively.

After application of the Bonferroni correction to account for multiple testing issues, P-values with P < 0.008 were considered statistically significant and values of $0.008 \le P < 0.05$ as suggestive significant. All reported ORs were expressed per one standard deviation increment of each body composition measure. Significance thresholds were set to α = 0.01 for testing particular Q statistics and α = 0.05 for the PRESSO global test. Analyses were performed using primarily the TwoSampleMR (version 0.5.4), MendelianRandomization (version 0.5.0), MVMR (version 0.2) and MRPRESSO (version 1.0) packages of the statistical Software R (version: 4.0.0).

RESULTS

Total effects

Genetically predicted BMI was significantly positively associated with both, COVID-19 susceptibility (OR = 1.31; 95 % CI: 1.15 - 1.50; P-value = $7.3 \cdot 10^{-5}$) and hospitalization (OR = 1.62; 95 % CI: 1.33 - 1.99; P-value = $2.8 \cdot 10^{-6}$) due to severe symptoms of COVID-19 [Tables 2-3]. While genetically predicted TFR showed a strong relationship with disease susceptibility (OR = 1.42; 95 % CI: 1.13 - 1.78; P-value = 0.003), the association with severity was weaker regarding wider confidence intervals despite a higher OR and therefore suggestive significant due to the Bonferroni corrected threshold of 0.008 (OR = 1.56; 95 % CI: 1.01 - 2.40; P-value = 0.044). Beyond that, there was suggestive evidence of a positive association between WC and COVID-19 susceptibility (OR = 1.38; 95 % CI: 1.07 - 1.78; P-value = 0.015) but not with hospitalization due to COVID-19 (OR = 1.47; 95 % CI: 0.97 - 2.23; P-value = 0.069).

Within an iterative approach with up to 3 iterations, SNP-specific Q_j statistics for particular genetic instruments revealed 5 outlier-SNPs in models with BMI on susceptibility as well as hospitalization and 1 outlier for the association of TFR with susceptibility [Supplementary Table S7]. However, exclusion of these variants had not a substantial effect on the appropriate estimates [Figure 2]. Regarding global Cochran's Q and Rücker's Q' statistics as well as the differences Q-Q' with $P_{min} > 0.407$ and the ratios $\frac{Q'}{Q} \approx 1$ there was no evidence for any pleotropic effect in the final models [Supplementary Table S6]. Additionally, neither MR-PRESSO global tests nor the radial MR-Egger intercept tests indicated horizontal or directional pleiotropy, respectively [Supplementary Table S5]. Therefore, all of the causal estimates above representing the magnitude of the effect of one standard deviation in the body composition measures) were obtained by the radial IVW model using modified second order weights. The estimated

causal effects by the radial method were equal to those of the standard IVW method with multiplicative random effects. All methods within sensitivity analyses led to consistent results (suggested positive SNP-outcome associations) supporting the findings revealed by the radial IWV models [Tables 2-3]. Especially the robust RAPS and PRESSO models led to the same decisions as the IVW approach.

Direct effects

After mutual adjustment for WC or TFR within the MVMR setting, genetically predicted BMI was still significantly positively associated with both, COVID-19 susceptibility and severity with odds ratios between $OR_{TFR adj} = 1.29$ (95 % CI: 1.07 – 1.54; P-value = 0.007) and $OR_{WC adj} = 2.13$ (95 % CI: 1.17 – 3.89; P-value = 0.014) [Figure 3]. Beyond that, the effect estimates of both visceral obesity traits lost their statistical significance after adjustment for BMI. The MVMR-Egger approach with multiplicative random effects as well as the Median method supported largely these findings [Supplementary Figure S12]. However, the Egger intercept test in the model of BMI together with TFR on the hospitalization due to COVID-19 revealed directional pleiotropy ($\beta_{Intercept} = 0.01$; 95 % CI: 0.00 – 0.02; P-value = 0.044) and a non-significant MR-Egger estimator for BMI in a different direction (OR = 0.74; 95 % CI: 0.36 – 1.51; P-value = 0.408) [Supplementary Figure S12]. Apart from this, there was no evidence for directional pleiotropy [Supplementary Table S8] or heterogeneity [Supplementary Table S9] in the multivariable models, what was supported by the point estimates of the multivariable Q-minimization approach, which is even consistent even with weak instruments [Figure 3].

Mediation analysis

Neither type 2 diabetes nor CVD nor both together mediated the effect of genetically predicted BMI on both COVID-19 outcomes [Figure 4]. Compared to the unadjusted OR_{total} the direct effect estimates of BMI on the susceptibility remained the same or increased slightly after adjustment for the particular mediators up to an $OR_{joint} = 1.38$ (95 % CI: 1.15 - 1.66; P-value = $4.7 \cdot 10^{-4}$) in the joint model with both mediator variables. For the outcome hospitalization the direct effect estimates remained also significant ranging between the type 2 diabetes--adjusted $OR_{T2D adj} = 1.56$ (95 % CI: 1.22 - 2.00; P-value = $4.8 \cdot 10^{-4}$) and CVD-adjusted $OR_{CVD adj} = 1.66$ (95 % CI: 1.29 - 2.13; P-value = $8.3 \cdot 10^{-5}$).

Furthermore, except for the joint model, a mediation effect by type 2 diabetes or CVD could not be observed for the association between genetically predicted WC and susceptibility to COVID-19 with direct effects similar to the total effects. Consideration of mediation mechanisms for the relationship of instrumented WC with hospitalization was not necessary due to lack of significance in the univariable MR approach.

The adjusted causal estimates for the impact of genetically predicted TFR on hospitalization due to COVID-19 ranging between $OR_{CVD adj} = 1.71$ (95 % CI: 1.09 – 2.68; P-value = 0.019) and $OR_{T2D adj} = 2.58$ (95 % CI: 1.66 – 4.01; P-value = 2.6 · 10⁻⁵) were stronger than the total effect estimates. This implies that TFR was neither mediated by type 2 diabetes nor CVD nor by both together. However, the association of genetically predicted TFR with susceptibility to an infection with COVID-19 was mediated by CVD ($OR_{CVD adj} = 1.43$; 95 % CI: 0.98 – 2.09; P-value = 0.061), but neither by type 2 diabetes ($OR_{T2D adj} = 1.58$; 95 % CI: 1.17 – 2.14; P-value = 0.003) nor in the joint model ($OR_{joint} = 1.41$; 95 % CI: 1.01 – 1.95; P-value = 0.043).

All estimates replicated by MVMR-Egger as well as Median approaches in our sensitivity analyses supported unfailingly the presented findings obtained by the robust IVW method with multiplicative random effects [Supplementary Figures S13 – S15]. Furthermore, there was no evidence for directional pleiotropy [Supplementary Table S10]. However, although the calculated Q-statistics revealed substantial heterogeneity in the joint models and type 2 diabetes-adjusted models of BMI on susceptibility and hospitalization due to COVID-19 [Supplementary Table S11], the calculated point estimates from the multivariable Q-minimization approach confirmed the appropriate findings of our mediation analyses [Figure 4].

DISCUSSION

The present study using genetic instruments for BMI, WC, and TFR from publicly available large-scale GWAS provides evidence for a causal role of general obesity expressed by an increasing BMI regarding COVID-19 susceptibility and disease severity. The association was strongly positive even after adjustment for genetically predicted visceral fat. Adjusting for the genetic effects of type 2 diabetes and CVD, the direct causal effects of BMI were not attenuated and thus, a mediating effect of these comorbidities seems unlikely. In view of the visceral obesity traits, especially

the TFR had a significant total but not direct effect on both outcomes, while the association with COVID-19 susceptibility may be mediated by CVD.

The present MR-analysis supports recently published observational studies, systematic reviews and meta-analyses assuming that obesity defined by BMI might be an independent risk factor for COVID-19^{9-12,28}. In addition, the results of this MR-analysis clearly indicated a causal association of BMI and COVID-19 susceptibility and severity independent of the comorbidities type 2 diabetes and CVD. This finding is in line with two other MR-studies investigating the among other risk factors the association between genetically predicted BMI and COVID-19 identified BMI as a causal risk factor for COVID-19 susceptibility and severity^{13,14}. One further prior MR-study on cardiometabolic risk factors associated with COVID-19 identified BMI as a causal risk factor for COVID-19 susceptibility and severity¹⁵. Contrary to our findings, in that investigation, the authors concluded that the association between BMI and COVID-19 illness might be mediated by type 2 diabetes. However, in contrast to the study of Leong et al. in our investigation we used the latest mediation GWASs with no sample overlap with the selected datasets of body composition measures. This approach circumvented issues with estimations of phenotypic covariances and therefore minimized bias within the mediation analyses²⁵.

So far, studies investigating the role of body fat distribution on the severity and susceptibility of COVID-19 are scarce. Few observational studies investigated the association between visceral fat and COVID-19 disease severity and complications and suggested that abdominal fat is related to disease severity²⁹⁻³³. For example, in their proof-ofconcept study including 30 patients with COVID-19 Petersen et al. suggested that visceral fat and upper abdominal circumference specifically increased the likelihood of severe COVID-19³¹. Another study showed that visceral adiposity and high intramuscular fat deposition assessed by computed tomography scans were independently associated with critical COVID-19 illness, that is patients with acute respiratory distress syndrome or sepsis with acute organ dysfunction³². Our results show that, apart from BMI, body fat distribution, in particular visceral adiposity, plays no direct causal role regarding COVID-19 severity and susceptibility. Observational studies on correlations of visceral fat accumulation with COVID-19 can be subject to biases including residual confounding and reverse causality.

Several mechanisms may explain why obese people are at increased risk for COVID-19 infection. Inflammation and the immune system in obese individuals could play a role in relation to viral diseases. In adipose tissue there is a high

production of pro-inflammatory cytokines causing chronic low-grade inflammation and immune dysregulation^{34,35}. Results from animal models revealed that the role of obesity in increasing the risk of influenza morbidity and mortality is due to the impairment of the immune response to this pathogen³⁶. Green et al. proposed that hyperinsulinemia or hyperleptinemia which occurs predominantly in obese subjects may lead to a metabolic dysregulation of T cells, resulting in an impairment of the activation and function of these adaptive immune cells in response to influenza viruses³⁶. In this context, Honce et al. emphasized especially the role of visceral adiposity³⁷. Which metabolic and immune derangements in obese people are responsible for the increased susceptibility to COVID-19 infections should be subject of further research.

In connection with COVID-19 it is discussed that the SARS-CoV receptor ACE2 is also used by the SARS-CoV-2 spike protein (a special surface glycoprotein) as a cellular entry receptor³⁸. In human tissue ACE2 is expressed in the lung, the main target site for COVID-19 infection, but also in extrapulmonary tissues including heart, kidney, and intestine. Furthermore, obesity upregulates ACE2 receptor and therefore obese subjects have larger amounts of ACE2³⁹. It can be assumed that analogous to SARS-CoV⁴⁰, excessive ACE2 may competitively bind with SARS-CoV-2 not only to neutralize the virus but also to rescue cellular ACE2 activity which negatively regulates the renin-angiotensin system to protect the lung from injury⁴¹. Through the downregulation of ACE2 activity angiotensin II, the substrate for ACE, will accumulate and lead to increased neutrophil accumulation, increased vascular permeability, and pulmonary oedema, which will eventually cause severe lung injury. Because obesity is associated with a dysregulation of the renin-angiotensin-aldosterone system and thus among other things linked to an overexpression of angiotensin II⁴², this is likely an important link between obesity and severity of COVID-19.

Strengths of the study include that we performed a range of robust MR methods to conduct sensitivity analyses for different patterns of pleiotropy, investigated total and direct effects and assessed mediation mechanisms at once. The use of three body composition measures, that have different views on body fat distribution, allowed us to compare as well as differentiate between overall and abdominal fat content. Moreover, the used TFR summary level data, which based on exact measurement procedure instead of approximation, allowed us to verify the results of usually used WC-GWAS and on this way to strengthen the evidence. However, our study also has limitations. The relationship between obesity and the risk of acquiring COVID-19 disease is influenced by selection bias, because people with no, uncomplicated or milder symptoms often were not tested regarding SARS-CoV-2 infection. This

causes bias towards the null hypothesis due to false negatives (type II error) and reduces therefore the power by underestimating the true causal effect. Sex-specific samples would lead to higher precision, although we did not expect large differences between men and women. Furthermore, the present study was conducted in subjects of European ancestry and therefore the findings could not be applied to other ethnicities.

Our study is the first strengthening the evidence that overall and not abdominal obesity is causally associated with the susceptibility to and the severity of COVID-19 disease. Future research is necessary to investigate the underlying mechanisms linking obesity with COVID-19. Since the prevalence of obesity is still increasing in many countries and the probability of emerging and re-emerging infectious diseases might be high in the future⁴³, intensive public health interventions targeting obesity are necessary to reduce morbidity and mortality due to infectious diseases such as COVID-19.

Author Contributions

DF analyzed the data and created the tables and figures. CM did the literature research and contributed together with DF to the data collection. Authors JL and CM reviewed and edited the paper. All authors wrote the paper and contributed to the data interpretation.

Funding

The authors did not receive funding for this study. Funding information of the genome-wide association studies is specified in the cited studies.

Conflict of interest

All authors declare that they have nothing to disclose.

Data availability

The present study is based on summary-level data that have been made publically available. Summary data from genome-wide association studies for the BMI (Locke et al.) and WC (Shungin et al.) are available at

https://portals.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium_data_files.Data for TFR (Rask-Andersenetal)canbeobtainedfromhttps://myfiles.uu.se/ssf/s/readFile/share/3993/1270878243748486898/publicLink/GWAS_summary_stats_ratios.zip20The COVID-19 GWAS summary data are available at https://www.covid19hg.org/results. Summary level data forT2D can be obtained from MRC IEU OpenGWAS Project database (https://gwas.mrcieu.ac.uk/datasets/finn-a-E4_DM2/) and for CVD from http://www.cardiogramplusc4d.org/data-downloads/. In all original studies, ethical approval had been obtained.

REFERENCES

- Organization, W. H. Coronavirus disease (COVID-19) pandemic,

 <<u>https://www.who.int/emergencies/diseases/novel-coronavirus-2019</u>> (2020, October 22).
- 2 Chen, J. *et al.* Clinical progression of patients with COVID-19 in Shanghai, China. *J Infect* **80**, e1-e6, doi:10.1016/j.jinf.2020.03.004 (2020).
- 3 Aggarwal, G. *et al.* Association of Cardiovascular Disease With Coronavirus Disease 2019 (COVID-19) Severity: A Meta-Analysis. *Curr Probl Cardiol* **45**, 100617, doi:10.1016/j.cpcardiol.2020.100617 (2020).
- 4 Mantovani, A., Byrne, C. D., Zheng, M. H. & Targher, G. Diabetes as a risk factor for greater COVID-19 severity and in-hospital death: A meta-analysis of observational studies. *Nutr Metab Cardiovasc Dis* **30**, 1236-1248, doi:10.1016/j.numecd.2020.05.014 (2020).
- 5 Docherty, A. B. *et al.* Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol. *medRxiv*, 2020.2004.2023.20076042, doi:10.1101/2020.04.23.20076042 (2020).
- 6 Petrilli, C. M. *et al.* Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease in New York City. *medRxiv*, 2020.2004.2008.20057794, doi:10.1101/2020.04.08.20057794 (2020).
- 7 Williamson, E. *et al.* OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. *medRxiv*, 2020.2005.2006.20092999, doi:10.1101/2020.05.06.20092999 (2020).
- 8 Du, Y., Lv, Y., Zha, W., Zhou, N. & Hong, X. Association of Body mass index (BMI) with Critical COVID-19 and in-hospital Mortality: a dose-response meta-analysis. *Metabolism*, 154373, doi:10.1016/j.metabol.2020.154373 (2020).
- al., S. A. C. M. P. J. R. V. e. High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Requiring Invasive Mechanical Ventilation. *Obesity (Silver Spring)* 28, 1994, doi:10.1002/oby.23006 (2020).
- 10 Lighter, J. *et al.* Obesity in Patients Younger Than 60 Years Is a Risk Factor for COVID-19 Hospital Admission. *Clin Infect Dis* **71**, 896-897, doi:10.1093/cid/ciaa415 (2020).
- 11 Yang, J., Hu, J. & Zhu, C. Obesity aggravates COVID-19: A systematic review and meta-analysis. *J Med Virol*, doi:10.1002/jmv.26237 (2020).
- 12 Soeroto, A. Y. *et al.* Effect of increased BMI and obesity on the outcome of COVID-19 adult patients: A systematic review and meta-analysis. *Diabetes Metab Syndr* **14**, 1897-1904, doi:10.1016/j.dsx.2020.09.029 (2020).
- 13 Mark, P. J. *et al.* Cardiometabolic traits, sepsis and severe covid-19 with respiratory failure: a Mendelian randomization investigation. *medRxiv*, 2020.2006.2018.20134676, doi:10.1101/2020.06.18.20134676 (2020).
- 14 Ponsford, M. J. *et al.* Cardiometabolic Traits, Sepsis and Severe COVID-19: A Mendelian Randomization Investigation. *Circulation*, doi:10.1161/CIRCULATIONAHA.120.050753 (2020).
- Leong, A. *et al.* Cardiometabolic Risk Factors for COVID-19 Susceptibility and Severity: A Mendelian Randomization Analysis. *medRxiv*, doi:10.1101/2020.08.26.20182709 (2020).
- 16 Burgess, S., Foley, C. N. & Zuber, V. Inferring Causal Relationships Between Risk Factors and Outcomes from Genome-Wide Association Study Data. *Annu Rev Genomics Hum Genet* **19**, 303-327, doi:10.1146/annurevgenom-083117-021731 (2018).
- 17 Davies, N. M., Holmes, M. V. & Davey Smith, G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. *BMJ* **362**, k601, doi:10.1136/bmj.k601 (2018).
- 18 Burgess, S. & Thompson, S. G. *Mendelian randomization : methods for using genetic variants in causal estimation.* (CRC Press, Taylor & Francis Group, 2015).
- 19 Sanderson, E., Davey Smith, G., Windmeijer, F. & Bowden, J. An examination of multivariable Mendelian randomization in the single-sample and two-sample summary data settings. *Int J Epidemiol* **48**, 713-727, doi:10.1093/ije/dyy262 (2019).
- 20 Rask-Andersen, M., Karlsson, T., Ek, W. E. & Johansson, A. Genome-wide association study of body fat distribution identifies adiposity loci and sex-specific genetic effects. *Nat Commun* **10**, 339, doi:10.1038/s41467-018-08000-4 (2019).

- Pulit, S. L. *et al.* Meta-analysis of genome-wide association studies for body fat distribution in 694 649 individuals of European ancestry. *Hum Mol Genet* **28**, 166-174, doi:10.1093/hmg/ddy327 (2019).
- 22 Shungin, D. *et al.* New genetic loci link adipose and insulin biology to body fat distribution. *Nature* **518**, 187-196, doi:10.1038/nature14132 (2015).
- 23 Elsworth, B. *et al.* The MRC IEU OpenGWAS data infrastructure. *bioRxiv*, 2020.2008.2010.244293, doi:10.1101/2020.08.10.244293 (2020).
- 24 Schunkert, H. *et al.* Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. *Nat Genet* **43**, 333-338, doi:10.1038/ng.784 (2011).
- 25 Sanderson, E., Spiller, W. & Bowden, J. Testing and Correcting for Weak and Pleiotropic Instruments in Two-Sample Multivariable Mendelian Randomisation. *bioRxiv*, 2020.2004.2002.021980, doi:10.1101/2020.04.02.021980 (2020).
- 26 Initiative, C.-H. G. The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic. *Eur J Hum Genet* **28**, 715-718, doi:10.1038/s41431-020-0636-6 (2020).
- 27 Burgess, S. Sample size and power calculations in Mendelian randomization with a single instrumental variable and a binary outcome. *Int J Epidemiol* **43**, 922-929, doi:10.1093/ije/dyu005 (2014).
- 28 Seidu, S. *et al.* The impact of obesity on severe disease and mortality in people with SARS-CoV-2: A systematic review and meta-analysis. *Endocrinol Diabetes Metab*, e00176, doi:10.1002/edm2.176 (2020).
- 29 Chandarana, H. *et al.* Visceral adipose tissue in patients with COVID-19: risk stratification for severity. *Abdom Radiol (NY)*, doi:10.1007/s00261-020-02693-2 (2020).
- Watanabe, M. *et al.* Visceral fat shows the strongest association with the need of intensive care in patients with COVID-19. *Metabolism* **111**, 154319, doi:10.1016/j.metabol.2020.154319 (2020).
- 31 Petersen, A. *et al.* The role of visceral adiposity in the severity of COVID-19: Highlights from a unicenter cross-sectional pilot study in Germany. *Metabolism* **110**, 154317, doi:10.1016/j.metabol.2020.154317 (2020).
- 32 Yang, Y. *et al.* Visceral Adiposity and High Intramuscular Fat Deposition Independently Predict Critical Illness in Patients with SARS-CoV-2. *Obesity (Silver Spring)*, doi:10.1002/oby.22971 (2020).
- 33 lacobellis, G., Malavazos, A. E. & Ferreira, T. COVID-19 Rise in Younger Adults with Obesity: Visceral Adiposity Can Predict the Risk. *Obesity (Silver Spring)* **28**, 1795, doi:10.1002/oby.22951 (2020).
- Reilly, S. M. & Saltiel, A. R. Adapting to obesity with adipose tissue inflammation. *Nat Rev Endocrinol* **13**, 633-643, doi:10.1038/nrendo.2017.90 (2017).
- Lackey, D. E. & Olefsky, J. M. Regulation of metabolism by the innate immune system. *Nat Rev Endocrinol* **12**, 15-28, doi:10.1038/nrendo.2015.189 (2016).
- Green, W. D. & Beck, M. A. Obesity Impairs the Adaptive Immune Response to Influenza Virus. *Ann Am Thorac Soc* **14**, S406-S409, doi:10.1513/AnnalsATS.201706-447AW (2017).
- 37 Honce, R. & Schultz-Cherry, S. Impact of Obesity on Influenza A Virus Pathogenesis, Immune Response, and Evolution. *Front Immunol* **10**, 1071, doi:10.3389/fimmu.2019.01071 (2019).
- Hoffmann, M., Kleine-Weber, H. & Pohlmann, S. A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells. *Mol Cell* 78, 779-784 e775, doi:10.1016/j.molcel.2020.04.022 (2020).
- 39 Engeli, S. *et al.* The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome? *Int J Biochem Cell Biol* **35**, 807-825, doi:10.1016/s1357-2725(02)00311-4 (2003).
- 40 Kuba, K. *et al.* A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury. *Nature Medicine* **11**, 875-879, doi:10.1038/nm1267 (2005).
- 41 Imai, Y. *et al.* Angiotensin-converting enzyme 2 protects from severe acute lung failure. *Nature* **436**, 112-116, doi:10.1038/nature03712 (2005).
- 42 Akoumianakis, I. & Filippatos, T. The renin-angiotensin-aldosterone system as a link between obesity and coronavirus disease 2019 severity. *Obes Rev*, doi:10.1111/obr.13077 (2020).
- 43 Semenza, J. C. *et al.* Determinants and Drivers of Infectious Disease Threat Events in Europe. *Emerg Infect Dis* 22, 581-589, doi:10.3201/eid2204 (2016).

Table 1 Characteristics of the Single Nucleotide Polymorphisms (SNPs) used as instrumental variables for body mass index (BMI), waist circumference (WC), and trunk fat ratio (TFR) in the two-sample Mendelian randomization analyses

	BMI	WC	TFR
Sample size	694,649	232 101	362,499
Consortium	GIANT, UK Biobank	GIANT	UK Biobank
Number of instrumental SNPs ^a	524	42	33
Explained variance	5.51 %	1.09 %	1.25 %
F-statistic (mean, range)	72.29 (28.44 – 1,270.71)	55.26 (29.34 – 447.02)	41.69 (30.26 – 124.77)
Reference	Pulit et al, 2018	Shungin et al, 2015	Rask-Andersen et al, 2019

^a extraction of SNPs based on the threshold $\alpha = 5 \cdot 10^{-8}$ and clumping cutoff $r^2 = 0.001$.

Table 2 Univariable Mendelian randomization estimates (total effects) for the association between body mass index (BMI), waist circumference (WC), and trunk fat ratio (TFR) related Single Nucleotide Polymorphisms (SNPs) and COVID-19 susceptibility

Method	n _{SNP}	OR	95 % Cl	Р	Exposure
Radial IVW (Mod.2nd)	519	1.312	(1.147 - 1.500)	7.3·10 ⁻⁵	BMI
Radial IVW (exact fixed effects)	519	1.317	(1.148 - 1.510)	8 1 10 ⁻⁵	BMI
Radial IVW (exact random effects)	519	1.317	(1.153 - 1.504)	5.5·10 ⁻⁵	BMI
IVW (mult. random effects)	519	1.312	(1.147 - 1.500)	7.3 10 ⁻⁵	BMI
RAPS	519	1.317	(1.146 - 1.513)	$1.0 \cdot 10^{-4}$	BMI
PRESSO	519	1.312	(1.147 - 1.500)	8.3·10 ⁻⁵	BMI
Weighted median	519	1.333	(1.077 - 1.650)	0.008	BMI
Weighted mode	519	1.414	(0.887 - 2.255)	0.146	BMI
MR-Egger	519	1.297	(0.884 - 1.905)	0.184	BMI
Radial IVW (Mod.2nd)	41	1.377	(1.065 - 1.780)	0.015	WC
Radial IVW (exact fixed effects)	41	1.384	(1.040 - 1.843)	0.026	WC
Radial IVW (exact random effects)	41	1.384	(1.089 - 1.760)	0.011	WC
IVW (mult. random effects)	41	1.377	(1.065 - 1.780)	0.015	WC
RAPS	41	1.384	(1.033 - 1.855)	0.029	WC
PRESSO	41	1.377	(1.065 - 1.780)	0.019	WC
Weighted median	41	1.362	(0.904 - 2.053)	0.139	WC
Weighted mode	41	1.296	(0.670 - 2.507)	0.445	WC
MR-Egger	41	1.817	(0.654 - 5.050)	0.259	WC
Radial IVW (Mod.2nd)	32	1.417	(1.126 - 1.783)	0.003	TFR
Radial IVW (exact fixed effects)	32	1.424	(1.069 - 1.897)	0.016	TFR
Radial IVW (exact random effects)	32	1.424	(1.136 - 1.785)	0.004	TFR
IVW (mult. random effects)	32	1.417	(1.126 - 1.783)	0.003	TFR
RAPS	32	1.424	(1.061 - 1.913)	0.019	TFR
PRESSO	32	1.417	(1.126 - 1.783)	0.006	TFR
Weighted median	32	1.411	(0.944 - 2.109)	0.093	TFR
Weighted mode	32	1.526	(0.766 - 3.041)	0.238	TFR
MR-Egger	32	1.746	(0.564 - 5.405)	0.341	TFR

Abbrevations: OR, odds ratio; CI, confidence interval; IVW (Mod.2nd) inverse-variance weighted model with modified 2nd order weights.

Table 3 Univariable Mendelian randomization estimates (total effects) for the association between body mass index (BMI), waist circumference (WC), and trunk fat ratio (TFR) related Single Nucleotide Polymorphisms (SNPs) and hospitalization due to severity of COVID-19 disease

Method	n _{SNP}	OR	95 % Cl	Р	Exposure
Radial IVW (Mod.2nd)	518	1.623	(1.325 - 1.989)	2.8 10 ⁻⁶	BMI
Radial IVW (exact fixed effects)	518	1.635	(1.336 - 2.002)	1 8 10 ⁻⁶	BMI
Radial IVW (exact random effects)	518	1.635	(1.340 - 1.996)	1.7 10 ⁻⁶	BMI
IVW (mult. random effects)	518	1.623	(1.325 - 1.989)	2.8 10 ⁻⁶	BMI
RAPS	518	1.635	(1.332 - 2.008)	2.6 10 ⁻⁶	BMI
PRESSO	518	1.623	(1.325 - 1.989)	3 6 10 ⁶	BMI
Weighted median	518	1.544	(1.103 - 2.161)	0.011	BMI
Weighted mode	518	1.271	(0.629 - 2.571)	0.504	BMI
MR-Egger	518	1.270	(0.721 - 2.237)	0.407	BMI
Radial IVW (Mod.2nd)	41	1.472	(0.971 - 2.232)	0.069	WC
Radial IVW (exact fixed effects)	41	1.483	(0.971 - 2.265)	0.068	WC
Radial IVW (exact random effects)	41	1.483	(0.992 - 2.217)	0.062	WC
IVW (mult. random effects)	41	1.472	(0.971 - 2.232)	0.069	WC
RAPS	41	1.483	(0.962 - 2.285)	0.074	WC
PRESSO	41	1.472	(0.971 - 2.232)	0.076	WC
Weighted median	41	1.441	(0.788 - 2.633)	0.235	WC
Weighted mode	41	1.240	(0.442 - 3.477)	0.685	WC
MR-Egger	41	1.640	(0.365 - 7.360)	0.523	WC
Radial IVW (Mod.2nd)	33	1.560	(1.013 - 2.404)	0.044	TFR
Radial IVW (exact fixed effects)	33	1.577	(1.036 - 2.402)	0.034	TFR
Radial IVW (exact random effects)	33	1.576	(1.028 - 2.418)	0.045	TFR
IVW (mult. random effects)	33	1.560	(1.013 - 2.404)	0.044	TFR
RAPS	33	1.577	(1.025 - 2.427)	0.038	TFR
PRESSO	33	1.560	(1.013 - 2.404)	0.052	TFR
Weighted median	33	1.643	(0.906 - 2.979)	0.102	TFR
Weighted mode	33	1.700	(0.519 - 5.566)	0.387	TFR
MR-Egger	33	3.254	(0.565 - 18.751)	0.196	TFR

Abbrevations: OR, odds ratio; CI, confidence interval; IVW (Mod.2nd) inverse-variance weighted model with modified 2nd order weights.



Figure 1 Simplified illustration showing the difference between a direct and total effect using two exposures in a Mendelian randomization setting. G represents a set valid genetic instruments of two exposures X_1 and/or X_2 . Bidirectional arrows represent possible violations of the IV assumptions induced by X_2 . The direct effect of exposure X_1 on outcome Y is illustrated by the path a between X_1 and Y. By contrast, the total effect of X_1 is defined as the sum of all paths from X_1 on Y (a, b and c).



Figure 2 Causal total effect estimates (odds ratios and 95 % confidence intervals) from the univariable Mendelian randomization analyses of body mass index (BMI), waist circumference (WC), and trunk fat ratio (TFR) with COVID-19 susceptibility and hospitalization. Grey points with dashed confidence intervals correspond to estimates biased regarding influential SNPs [Supplementary Table S7]. For reasons of clarity MR-Egger estimates were omitted regarding wide confidence intervals.

Abbrevations: IVW (Mod.2nd) inverse-variance weighted model with modified 2nd order weights.



Figure 3 Causal direct effect estimates from pairwise multivariable Mendelian randomization analyses of body mass index (BMI), waist circumference (WC), and trunk fat ratio (TFR) with COVID-19 susceptibility as well as hospitalization. Odds ratios and 95 % confidence intervals were obtained from the robust inverse-variance weighted (IVW) method with multiplicative random effects. Point estimates shown as asterisks were obtained from the Q-minimization approach that account for weak instruments and substantial heterogeneity.



Figure 4 Total and direct effect estimates from Mendelian randomization mediation analyses of body composition measures, body mass index (BMI), waist circumference (WC), and trunk fat ratio (TFR), adjusted for type 2 diabetes (T2D) and/or cardiovascular diseases (CVD) on COVID-19 susceptibility as well as hospitalization. Odds ratios and 95 % confidence intervals were obtained from the robust inverse-variance weighted method with multiplicative random

effects. Point estimates shown as asterisks were obtained from the Q-minimization approach that account for weak instruments and substantial heterogeneity.



